Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis

NCT03215277 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT03215277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03215277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Completed
Start date
October 4, 2017
Completion date
May 25, 2020
Enrollment
76 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis